Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Alectinib
Treatment for Tracheal, bronchus, and lung cancer
Typical Dosage: 600 mg orally twice daily
Effectiveness
88%
Safety Score
32%
Clinical Trials
200
Participants
15K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
32
DangerousModerateSafe
Treatment Details
Dosage Range
600 mg orally twice daily
Time to Effect
6-8 weeks
Treatment Duration
Until disease progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$185,000
Monitoring:$7,000
Side Effect Mgmt:$5,000
Total Annual:$197,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.76
Outcome-Based Costs
Cost per Responder
$262,667
Cost per Remission
$4,925,000
Comparison vs Crizotinib
Cost Difference
+$35,000/year
More expensive
QALY Difference
+0.76 QALYs
Better outcomes
Dominance
No dominance
Alectinib Outcomes
for Tracheal, bronchus, and lung cancer
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Remission Rate
+4%
Common Side Effects
Fatigue
+50%
Myalgia
+40%
Edema
+40%
Anemia
+30%
Constipation
+30%
Liver enzyme elevation
+20%
Bradycardia
+15%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov